QSC supplies Raloxifene (SERM) and Exemestane (steroidal aromatase inhibitor) for laboratory research. Both are used in oestrogen receptor biology, aromatase enzyme studies, breast cancer models, male hypogonadism, and post-cycle HPG axis research. Available as tablet kits with ≥99% purity and Janoshik independent COA.
Raloxifene is a second-generation SERM: agonist at ER in bone and liver, antagonist in breast and uterus. FDA-approved for osteoporosis and breast cancer risk reduction. Research use: bone mineral density, ERa/ERb selectivity, breast cancer chemoprevention, male gynecomastia, PCT.
Exemestane is a Type I (steroidal) aromatase inhibitor that irreversibly inactivates CYP19A1 (“suicide inhibition”) — mechanistically distinct from reversible Type II AIs (anastrozole, letrozole). FDA-approved for breast cancer. Research use: oestrogen suppression in hormone-sensitive cancer models, male hypogonadism from aromatase excess, aromatase kinetics, testosterone:oestradiol ratio.
Breast cancer, oestrogen suppression, male hypogonadism, aromatase kinetics
SERM vs AI — mechanistic distinction for research design
Raloxifene competes with oestradiol at the receptor — it does not reduce oestradiol levels. Exemestane reduces oestradiol production by blocking synthesis. Combining both allows independent study of receptor-level vs ligand-level oestrogen modulation. For PCT research, SERMs restore HPG axis without fully suppressing oestrogen. For male hypogonadism from aromatase excess, AIs directly reduce oestradiol production.
